CRISPR Nuclease Portfolio Expanded with Addition of Eureca-V

CRISPR protein, Eureca-V™ Nuclease is the most recent addition to our catalog. It is based on the proprietary MAD7® nuclease developed by Inscripta®. Aldevron and Inscripta have partnered to make this protein broadly available to the therapeutic, diagnostic, and agricultural research markets.

Mechanism of Action & Benefits

Like all standard Aldevron nucleases in our catalog, Eureca-V has a simple construct design of:

Where sNLS is a standard SV40 Large T-antigen Nuclear Localization Signal. Eureca-V does not contain any affinity tags, nor are any used during the manufacture of this product.

Eureca-V is categorized as a Class 2, Type V CRISPR-Cas nuclease. It shares key features common to this family of CRISPR nucleases, including:

• Targets broad array of T-rich PAM domains (YTTV preferred, TTTN functions)
• Requires a single crRNA to cut target DNA sequence
• Staggered double-strand break at cut site creates 5’ overhangs

Why Eureca-V?

The planned launch of cGMP Eureca-V Nuclease will streamline client translational efforts and make it easier than ever to source a pharmaceutical-grade Type-V gene editing nuclease! We expect that Eureca-V will be the first Type-V nuclease on the market as a cGMP inventoried catalog product, presenting an attractive alternative to technology that is more challenging to license or secure freedom to operate.

As with the cGMP nucleases already in our catalog, cGMP Eureca-V will be fully supported as a drug substance by Aldevron’s dedicated Regulatory Affairs team. Aldevron is committed to supporting client filings with the FDA as well as international regulatory bodies. Our team can help to draft relevant sections of your regulatory filing and plans to submit a Drug Master File for Eureca-V™ upon release and completion of a real-time cGMP stability study.

Resources

• BROCHURE: Advancing CRISPR-based Therapeutic Development
• WHITEPAPER: Next-Generation CRISPR Approaches: Explore Strategies to Advance Therapeutic Programs Supporting Current Regulatory Guidance
• WHITEPAPER: Expectations on the Pathway to GMP for Gene-Modified Cell Therapies
• CASE STUDY: Enabling Novel CRISPR-Cas9 Delivery: A Case Study Supporting Innovative Genomics Insititute

Ordering Information